Human hematopoietic signal peptide-containing secreted 1 (hHSS1) modulates genes and pathways in glioma: implications for the regulation of tumorigenicity and angiogenesis

BMC Cancer

Katiana S Junes-Gill²  Chris E Lawrence²  Christopher J Wheeler¹  Ryan Cordner¹  Tristan G Gill³  Vernon Mar²  Liron Shiri²  Lena A Basile² 

[1] Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Rm. 2097, Los Angeles, CA 90048, USA

[2] Neumedicines Inc., 133 N Altadena Dr. #310, Pasadena, CA 91107, USA

[3] Ingenuity Systems, 1700 Seaport Blvd, 3rd Floor, Redwood City, CA 94063, USA

关键词: A172;    U87;    TCGA database;    Angiogenesis;    Cell invasion;    Cell migration;    C19orf63;    hHSS1;    Microarray;    Glioma;   

Others  :  1117940
DOI  :  10.1186/1471-2407-14-920

 received in 2014-02-07, accepted in 2014-11-27,  发布年份 2014

【 摘 要 】

Background

Human Hematopoietic Signal peptide-containing Secreted 1 (hHSS1) is a truly novel protein, defining a new class of secreted factors. We have previously reported that ectopic overexpression of hHSS1 has a negative modulatory effect on cell proliferation and tumorigenesis in glioblastoma model systems. Here we have used microarray analysis, screened glioblastoma samples in The Cancer Genome Atlas (TCGA), and studied the effects of hHSS1 on glioma-derived cells and endothelial cells to elucidate the molecular mechanisms underlying the anti-tumorigenic effects of hHSS1.

Methods

Gene expression profiling of human glioma U87 and A172 cells overexpressing hHSS1 was performed. Ingenuity® iReport™ and Ingenuity Pathway Analysis (IPA) were used to analyze the gene expression in the glioma cells. DNA content and cell cycle analysis were performed by FACS, while cell migration, cell invasion, and effects of hHSS1 on HUVEC tube formation were determined by transwell and matrigel assays. Correlation was made between hHSS1 expression and specific genes in glioblastoma samples in the TCGA database.

Results

We have clarified the signaling and metabolic pathways (i.e. role of BRCA1 in DNA damage response), networks (i.e. cell cycle) and biological processes (i.e. cell division process of chromosomes) that result from hHSS1effects upon glioblastoma growth. U87-overexpressing hHSS1 significantly decreased the number of cells in the G0/G1 cell cycle phase, and significantly increased cells in the S and G2/M phases (P < 0.05). U87-overexpressing hHSS1 significantly lost their ability to migrate (P < 0.001) and to invade (P < 0.01) through matrigel matrix. hHSS1-overexpression significantly decreased migration of A172 cells (P < 0.001), inhibited A172 tumor-induced migration and invasion of HUVECs (P < 0.001), and significantly inhibited U87 tumor-induced invasion of HUVECs (P < 0.001). Purified hHSS1 protein inhibited HUVEC tube formation. TCGA database revealed significant correlation between hHSS1 and BRCA2 (r = −0.224, P < 0.0005), ADAMTS1 (r = −0.132, P <0.01) and endostatin (r = 0.141, P < 0.005).

Conclusions

hHSS1-overexpression modulates signaling pathways involved in tumorigenesis. hHSS1 inhibits glioma-induced cell cycle progression, cell migration, invasion and angiogenesis. Our data suggest that hHSS1 is a potential therapeutic for malignant glioblastoma possessing significant antitumor and anti-angiogenic activity.

【 授权许可】

   
2014 Junes-Gill et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Wang X, Gong W, Liu Y, Yang Z, Zhou W, Wang M, Yang Z, Wen J, Hu R: Molecular cloning of a novel secreted peptide, INM02, and regulation of its expression by glucose. J Endocrinol 2009, 202(3):355-364.
• [2]Christianson JC, Olzmann JA, Shaler TA, Sowa ME, Bennett EJ, Richter CM, Tyler RE, Greenblatt EJ, Harper JW, Kopito RR: Defining human ERAD networks through an integrative mapping strategy. Nat Cell Biol 2011, 14(1):93-105.
• [3]Xu B, Hsu PK, Stark KL, Karayiorgou M, Gogos JA: Derepression of a neuronal inhibitor due to miRNA dysregulation in a schizophrenia-related microdeletion. Cell 2013, 152(1–2):262-275.
• [4]Junes-Gill KS, Gallaher TK, Gluzman-Poltorak Z, Miller JD, Wheeler CJ, Fan X, Basile LA: hHSS1: a novel secreted factor and suppressor of glioma growth located at chromosome 19q13.33. J Neurooncol 2011, 102(2):197-211.
• [5]Moore K, Kim L: Primary Brain Tumors: Characteristics, Pratical Diagnostic and Treatment Approaches. In Glioblastoma: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies Edited by Ray SK. 2010, 43-75.
• [6]Edgar R, Domrachev M, Lash AE: Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30(1):207-210.
• [7]O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T: A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993, 136(1–2):355-360.
• [8]Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998, 251(2):471-476.
• [9]Zou Y, Evans S, Chen J, Kuo HC, Harvey RP, Chien KR: CARP, a cardiac ankyrin repeat protein, is downstream in the Nkx2-5 homeobox gene pathway. Development 1997, 124(4):793-804.
• [10]Khodarev NN, Yu J, Labay E, Darga T, Brown CK, Mauceri HJ, Yassari R, Gupta N, Weichselbaum RR: Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 2003, 116(Pt 6):1013-1022.
• [11]Kanai H, Tanaka T, Aihara Y, Takeda S, Kawabata M, Miyazono K, Nagai R, Kurabayashi M: Transforming growth factor-beta/Smads signaling induces transcription of the cell type-restricted ankyrin repeat protein CARP gene through CAGA motif in vascular smooth muscle cells. Circ Res 2001, 88(1):30-36.
• [12]Stevens C, La Thangue NB: E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 2003, 412(2):157-169.
• [13]Law ME, Templeton KL, Kitange G, Smith J, Misra A, Feuerstein BG, Jenkins RB: Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet Cytogenet 2005, 160(1):1-14.
• [14]Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK: Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 2007, 67(17):7983-7986.
• [15]Fujisawa T, Joshi BH, Puri RK: IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 2012, 131(2):344-356.
• [16]Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK: In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 2001, 194(12):1743-1754.
• [17]Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JP: IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 2000, 164(5):2769-2775.
• [18]Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000, 6(5):2104-2119.
• [19]Ferla R, Bonomi M, Otvos L Jr, Surmacz E: Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects. BMC Cancer 2011, 11:303. BioMed Central Full Text
• [20]Roberts DD: Regulation of tumor growth and metastasis by thrombospondin- 1. FASEB J 1996, 10(10):1183-1191.
• [21]Roberts DD: THBS1 (thrombospondin-1). Atlas Genet Cytogenet Oncol Haematol 2005, 9(3):231-233.
• [22]Kawataki T, Naganuma H, Sasaki A, Yoshikawa H, Tasaka K, Nukui H: Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma. Neuropathology 2000, 20(3):161-169.
• [23]Naganuma H, Satoh E, Asahara T, Amagasaki K, Watanabe A, Satoh H, Kuroda K, Zhang L, Nukui H: Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells. Neurooncol 2004, 70(3):309-317.
• [24]Kälin RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, Brändli AW: Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol 2007, 305(2):599-614.
• [25]Kumar S, Sharghi-Namini S, Rao N, Ge R: ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity. Am J Pathol 2012, 181(3):1056-1068.
• [26]Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, Mangia A: VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer. PLoS One 2013, 8(1):e53070.
• [27]Dong Y, Sekine E, Fujimori A, Ochiya T, Okayasu R: Down regulation of BRCA2 causes radio-sensitization of human tumor cells in vitro and in vivo. Cancer Sci 2008, 99(4):810-815.
• [28]Abbott DW, Freeman ML, Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998, 90(13):978-985.
• [29]Quiros S, Roos WP, Kaina B: Rad51 and BRCA2–New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One 2011, 6(11):e27183.
• [30]Krampert M, Kuenzle S, Thai SN, Lee N, Iruela-Arispe ML, Werner S: ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells. J Biol Chem 2005, 280(25):23844-23852.
• [31]Su SC, Mendoza EA, Kwak HI, Bayless KJ: Molecular profile of endothelial invasion of three-dimensional collagen matrices: insights into angiogenic sprout induction in wound healing. Am J Physiol Cell Physiol 2008, 295(5):C1215-C1229.
• [32]Ricciardelli C, Frewin KM, Tan Ide A, Williams ED, Opeskin K, Pritchard MA, Ingman WV, Russell DL: The ADAMTS1 protease gene is required for mammary tumor growth and metastasis. Am J Pathol 2011, 179(6):3075-3085.
• [33]Peroulis I, Jonas N, Saleh M: Antiangiogenic activity of endostatin inhibits C6 glioma growth. Int J Cancer 2002, 97(6):839-845.
• [34]Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG: Endostatin blocks vascular endothelial growth factor mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002, 31:27872-27879.
• [35]Grossman R, Tyler B, Hwang L, Zadnik P, Lal B, Javaherian K, Brem H: Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. J Neurosurg 2011, 115(6):1139-1146.
• [36]Oklu R, Walker TG, Wicky S, Hesketh R: Angiogenesis and current antiangiogenic strategies for the treatment of cancer. J Vasc Interv Radiol 2010, 21(12):1791-1805.
• [37]Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, Popel AS: Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 2011, 12(8):1101-1116.
• [38]Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG: Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000, 60(19):5410-5413.
• [39]Folkman J: Tumor angiogenesis and tissue factor. Nature Med 1996, 2:167-168.
• [40]O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88(2):277-285.
• [41]Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, Brem H: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994, 57(6):920-925.